Novo Nordisk Leads Charge into $100B Obesity Market with Next-Gen Drugs
-
Novo Nordisk is working on next generation obesity drugs with different dosages and delivery methods beyond injectables. More details will be shared at its March investor day.
-
Several pharma companies like Pfizer, Amgen, and Roche are developing oral GLP-1 drugs and other formulations to compete with Novo and Lilly's leading injectables.
-
The obesity market is expected to be over $100 billion by 2030. Companies see room for multiple players across formulations.
-
Some companies like AstraZeneca and Merck are testing combo approaches by pairing GLP-1s with other drugs.
-
Beyond obesity, companies see potential for GLP-1s to treat other conditions like heart disease. More pivotal trial readouts are expected in 2024.